Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Debt: 2016-2025

Historic Non-Current Debt for Viridian Therapeutics, Inc.\DE (VRDN) over the last 6 years, with Sep 2025 value amounting to $20.9 million.

  • Viridian Therapeutics, Inc.\DE's Non-Current Debt rose 1.79% to $20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 1.79%. This contributed to the annual value of $20.6 million for FY2024, which is 1.87% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Non-Current Debt of $20.9 million as of Q3 2025, which was up 69.11% from $12.4 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Non-Current Debt peaked at $20.9 million during Q3 2025, and registered a low of $12.4 million during Q2 2025.
  • Its 3-year average for Non-Current Debt is $19.0 million, with a median of $20.5 million in 2024.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Non-Current Debt grew by 1.87% in 2024, and later fell by 29.36% in 2025.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's Non-Current Debt (Quarterly) stood at $20.2 million in 2023, then climbed by 1.87% to $20.6 million in 2024, then climbed by 1.79% to $20.9 million in 2025.
  • Its Non-Current Debt stands at $20.9 million for Q3 2025, versus $12.4 million for Q2 2025 and $20.7 million for Q1 2025.